clotrimazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	719	23593-75-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clotrimazole lotrimin rimazole locasten	An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal CELL MEMBRANES. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane. Molecular weight: 344.84 Formula: C22H17ClN2 CLOGP: 5 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 17.82 ALOGS: -5.37 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

clotrimazole
lotrimin
rimazole
locasten

An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal CELL MEMBRANES. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane.

Molecular weight: 344.84
Formula: C22H17ClN2
CLOGP: 5
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 17.82
ALOGS: -5.37
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	V

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	5 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	2.07 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Feb. 3, 1975	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	690.29	13.51	231	12870	18677	56260289
Schizoaffective disorder	311.16	13.51	82	13019	2867	56276099
Drug level increased	175.54	13.51	89	13012	20636	56258330
Electrocardiogram QT prolonged	105.08	13.51	93	13008	54495	56224471
Chronic sinusitis	73.89	13.51	37	13064	8341	56270625
Vulvovaginal candidiasis	58.20	13.51	23	13078	2963	56276003
Paraesthesia oral	57.55	13.51	38	13063	14411	56264555
Procedural pain	53.46	13.51	38	13063	16233	56262733
Rheumatoid arthritis	51.25	13.51	13	13088	382591	55896375
Sinus rhythm	44.46	13.51	13	13088	668	56278298
Oral candidiasis	42.25	13.51	35	13066	18728	56260238
Eye infection toxoplasmal	40.16	13.51	10	13091	277	56278689
Vanishing bile duct syndrome	40.02	13.51	12	13089	673	56278293
Drug interaction	35.15	13.51	118	12983	209637	56069329
Endocrine ophthalmopathy	34.50	13.51	10	13091	498	56278468
Swelling of eyelid	34.42	13.51	15	13086	2470	56276496
Toxic shock syndrome	32.44	13.51	10	13091	616	56278350
Candida infection	31.13	13.51	34	13067	25633	56253333
Dyspepsia	30.62	13.51	63	13038	83408	56195558
Purpura senile	29.75	13.51	9	13092	520	56278446
Tongue blistering	27.76	13.51	11	13090	1426	56277540
Febrile neutropenia	26.91	13.51	69	13032	105476	56173490
Vulvovaginal inflammation	26.51	13.51	9	13092	754	56278212
Tarsal tunnel syndrome	25.37	13.51	8	13093	531	56278435
Glossodynia	25.11	13.51	3	13098	152455	56126511
Swollen tongue	24.98	13.51	33	13068	30291	56248675
Nasal ulcer	24.46	13.51	11	13090	1951	56277015
Therapeutic product effect decreased	24.16	13.51	5	13096	169447	56109519
Eyelid disorder	23.77	13.51	10	13091	1511	56277455
Angiodermatitis	22.92	13.51	5	13096	76	56278890
Mean cell haemoglobin increased	22.35	13.51	11	13090	2389	56276577
Aplastic anaemia	20.82	13.51	17	13084	8911	56270055
Post viral fatigue syndrome	20.58	13.51	6	13095	305	56278661
Pelvic pain	20.41	13.51	19	13082	11848	56267118
Drug ineffective	20.06	13.51	312	12789	918677	55360289
Dyslipidaemia	18.96	13.51	14	13087	6339	56272627
Resorption bone increased	18.81	13.51	8	13093	1242	56277724
Discomfort	18.59	13.51	5	13096	141756	56137210
Fungal infection	18.58	13.51	30	13071	32963	56246003
Vestibular disorder	18.36	13.51	8	13093	1317	56277649
Vaginal infection	18.15	13.51	14	13087	6763	56272203
Drug intolerance	18.09	13.51	21	13080	264797	56014169
Stevens-Johnson syndrome	17.65	13.51	24	13077	22639	56256327
Reperfusion arrhythmia	17.55	13.51	5	13096	234	56278732
Vulvovaginal discomfort	17.49	13.51	9	13092	2146	56276820
Toxicity to various agents	17.37	13.51	16	13085	224548	56054418
Conjunctivitis	15.41	13.51	20	13081	18040	56260926
Congenital absence of bile ducts	15.10	13.51	3	13098	28	56278938
Hepatic enzyme increased	14.75	13.51	11	13090	171373	56107593
Dysuria	14.73	13.51	26	13075	30703	56248263
SARS-CoV-2 test negative	14.17	13.51	5	13096	470	56278496
Oedema mouth	14.14	13.51	8	13093	2302	56276664
Neuropathy peripheral	13.89	13.51	54	13047	102839	56176127
Stoma site haemorrhage	13.86	13.51	6	13095	972	56277994
Vulvovaginal pain	13.85	13.51	8	13093	2394	56276572
Swelling face	13.60	13.51	36	13065	56033	56222933
Post transplant distal limb syndrome	13.59	13.51	4	13097	210	56278756

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Temperature regulation disorder	25.60	15.63	8	6206	614	31690516
Cellulitis	21.76	15.63	36	6178	47982	31643148
Hypoglycaemia neonatal	20.60	15.63	9	6205	1773	31689357
Pulmonary vasculitis	20.57	15.63	6	6208	364	31690766
Skin infection	20.15	15.63	14	6200	6849	31684281
Lip haemorrhage	20.05	15.63	7	6207	759	31690371
Rash pruritic	19.89	15.63	24	6190	23914	31667216
Accident	19.07	15.63	11	6203	3900	31687230
Aplastic anaemia	18.59	15.63	15	6199	9188	31681942
Microtia	17.58	15.63	5	6209	277	31690853
Congenital umbilical hernia	17.31	15.63	5	6209	293	31690837
Neuritis	16.84	15.63	6	6208	690	31690440
Lymphopenia	16.43	15.63	17	6197	14312	31676818
Fluid replacement	16.34	15.63	4	6210	123	31691007
Fungal infection	16.21	15.63	17	6197	14534	31676596
Leukopenia	15.84	15.63	35	6179	57793	31633337

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	67.52	13.37	33	15523	7495	70905393
Chronic sinusitis	66.80	13.37	34	15522	8417	70904471
Vulvovaginal candidiasis	64.74	13.37	23	15533	2343	70910545
Paraesthesia oral	54.95	13.37	37	15519	15380	70897508
Procedural pain	47.54	13.37	36	15520	17973	70894915
Oral candidiasis	47.08	13.37	41	15515	24911	70887977
Aplastic anaemia	41.02	13.37	32	15524	16684	70896204
Swelling of eyelid	35.56	13.37	16	15540	3016	70909872
Rheumatoid arthritis	35.53	13.37	10	15546	291795	70621093
Eye infection toxoplasmal	34.48	13.37	10	15546	530	70912358
Endocrine ophthalmopathy	34.14	13.37	10	15546	549	70912339
Vanishing bile duct syndrome	32.65	13.37	12	15544	1347	70911541
Toxic shock syndrome	32.10	13.37	11	15545	1007	70911881
Rash pruritic	29.47	13.37	51	15505	62940	70849948
Dyspepsia	29.20	13.37	62	15494	89015	70823873
Tongue blistering	28.84	13.37	11	15545	1368	70911520
Toxicity to various agents	28.69	13.37	25	15531	382147	70530741
Tarsal tunnel syndrome	26.35	13.37	8	15548	497	70912391
Purpura senile	26.26	13.37	8	15548	503	70912385
Candida infection	26.22	13.37	35	15521	34438	70878450
Nasal ulcer	25.92	13.37	11	15545	1802	70911086
Swollen tongue	25.74	13.37	36	15520	37010	70875878
Febrile neutropenia	24.38	13.37	99	15457	204219	70708669
Pelvic pain	23.85	13.37	20	15536	11540	70901348
Eyelid disorder	23.59	13.37	10	15546	1634	70911254
Angiodermatitis	23.34	13.37	5	15551	74	70912814
Overdose	22.22	13.37	5	15551	169740	70743148
Stevens-Johnson syndrome	22.18	13.37	33	15523	35874	70877014
Drug ineffective	21.44	13.37	120	15436	939632	69973256
Therapeutic product effect decreased	21.35	13.37	3	15553	143015	70769873
Post viral fatigue syndrome	20.78	13.37	6	15550	313	70912575
Dyslipidaemia	20.22	13.37	17	15539	9843	70903045
Gingival swelling	19.92	13.37	12	15544	4117	70908771
Vaginal infection	19.60	13.37	13	15543	5265	70907623
Mean cell haemoglobin increased	18.85	13.37	11	15545	3562	70909326
Pruritus	18.84	13.37	135	15421	345425	70567463
Resorption bone increased	18.47	13.37	8	15548	1377	70911511
Fungal infection	18.39	13.37	31	15525	37436	70875452
Vulvovaginal inflammation	18.22	13.37	6	15550	486	70912402
Pulmonary vasculitis	18.21	13.37	6	15550	487	70912401
Urinary tract infection	17.73	13.37	104	15452	248665	70664223
Vulvovaginal discomfort	17.11	13.37	8	15548	1647	70911241
Wound complication	16.95	13.37	11	15545	4298	70908590
Reperfusion arrhythmia	16.85	13.37	5	15551	287	70912601
Oral mucosal blistering	16.67	13.37	12	15544	5544	70907344
Lip haemorrhage	16.35	13.37	7	15549	1172	70911716
Vulvovaginal pain	16.01	13.37	8	15548	1903	70910985
Plicated tongue	15.87	13.37	4	15552	124	70912764
Vulvovaginal mycotic infection	15.23	13.37	10	15546	3985	70908903
Genital rash	14.74	13.37	6	15550	886	70912002
Vestibular disorder	14.55	13.37	8	15548	2312	70910576
Swelling face	14.22	13.37	38	15518	63126	70849762
Kidney transplant rejection	14.20	13.37	14	15542	9947	70902941
Fluid replacement	14.02	13.37	4	15552	200	70912688
Eye infection	14.01	13.37	14	15542	10104	70902784
Accident	13.79	13.37	12	15544	7279	70905609
Post transplant distal limb syndrome	13.60	13.37	5	15551	562	70912326
Nephrogenic systemic fibrosis	13.59	13.37	11	15545	6041	70906847
Vasculitis	13.57	13.37	19	15537	19539	70893349
Cellulitis	13.47	13.37	50	15506	98878	70814010

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A01AB18	ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS STOMATOLOGICAL PREPARATIONS Antiinfectives and antiseptics for local oral treatment
ATC	D01AC01	DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Imidazole and triazole derivatives
ATC	G01AF02	GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Imidazole derivatives
FDA CS	M0002083	Azoles
FDA EPC	N0000175487	Azole Antifungal
CHEBI has role	CHEBI:35441	antiinfective agents
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:78298	environmental contaminants
MeSH PA	D058888	14-alpha Demethylase Inhibitors
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000891	Anti-Infective Agents, Local
MeSH PA	D000935	Antifungal Agents
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D065088	Steroid Synthesis Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Tinea pedis	indication	6020002	DOID:12403
Candidiasis of skin	indication	49883006
Pityriasis versicolor	indication	56454009	DOID:9060
Candidal vulvovaginitis	indication	72605008	DOID:2272
Candidiasis of mouth	indication	79740000	DOID:14262
Tinea corporis	indication	84849002
Diaper rash	indication	91487003
Tinea cruris	indication	399029005
Prevention of Oropharyngeal Candidiasis	indication
Oropharyngeal Candidiasis	indication
Paronychia	off-label use	71906005	DOID:13117
Telangiectasia disorder	contraindication	247479008
Abdominal pain - cause unknown	contraindication	314212008
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Atrophoderma	contraindication	399979006
Peripheral vascular disease	contraindication	400047006

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Fungal infections caused by Microsporum canis	Indication
Cats	Fungal infections caused by Trichophyton mentagrophytes	Indication
Cats	Otitis externa caused by yeast, Malassezia pachydermatis	Indication
Dogs	Fungal infections caused by Microsporum canis	Indication
Dogs	Fungal infections caused by Trichophyton mentagrophytes	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Veltrim 1% Dermatologic Cream	Elanco US Inc.	1
Otomax	Intervet Inc.	3
Mometamax Otic Suspension	Intervet Inc.	3
Tri-Otic Ointment	Med-Pharmex Inc.	3
Vetro-Max	Fougera Pharmaceuticals Inc.	3
GBC Ointment	Cronus Pharma Specialities India Private Limited	3
Mometavet	Med-Pharmex Inc.	3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.4	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN		Ki	5.19	DRUG MATRIX
Prostaglandin G/H synthase 2	Enzyme	P35354	PGH2_HUMAN		IC50	4.38	DRUG MATRIX
Nuclear receptor subfamily 1 group I member 3	Nuclear hormone receptor	Q14994	NR1I3_HUMAN	ANTAGONIST	IC50	6.16	IUPHAR
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN		Ki	6.14	DRUG MATRIX
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	5.35	DRUG MATRIX
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	5.39	DRUG MATRIX
Adenosine receptor A2a	GPCR	P29274	AA2AR_HUMAN		Ki	5.15	DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.35	DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5.52	CHEMBL
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	7.70	WOMBAT-PK
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	5.17	WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.51	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.10	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.00	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	5.50	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	5.13	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	5.12	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	5.24	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.43	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.05	DRUG MATRIX
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	5.47	DRUG MATRIX
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	5.78	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	5.29	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	5.68	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	5.79	DRUG MATRIX
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN		Ki	5.83	DRUG MATRIX
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN		Ki	5.27	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.35	DRUG MATRIX
Adenosine receptor A1	GPCR	P30542	AA1R_HUMAN		Ki	5.11	DRUG MATRIX
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.57	DRUG MATRIX
Intermediate conductance calcium-activated potassium channel protein 4	Ion channel	O15554	KCNN4_HUMAN		IC50	7.15	CHEMBL
Nuclear receptor subfamily 1 group I member 2	Nuclear hormone receptor	O75469	NR1I2_HUMAN				WOMBAT-PK
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	5.16	DRUG MATRIX
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		IC50	4.52	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	5.13	DRUG MATRIX
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		Ki	5.60	DRUG MATRIX
Delta-type opioid receptor	GPCR	P41143	OPRD_HUMAN		Ki	5.76	DRUG MATRIX
Acetylcholinesterase	Enzyme	P22303	ACES_HUMAN		IC50	4.71	DRUG MATRIX
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	7.80	DRUG MATRIX
Platelet-activating factor receptor	GPCR	P25105	PTAFR_HUMAN		Ki	4.65	DRUG MATRIX
Aromatase	Enzyme	P11511	CP19A_HUMAN		IC50	8.74	CHEMBL
Cysteinyl leukotriene receptor 1	GPCR	Q9Y271	CLTR1_HUMAN		Ki	4.78	CHEMBL
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		IC50	4.16	DRUG MATRIX
Vasopressin V2 receptor	GPCR	P30518	V2R_HUMAN		IC50	5.60	CHEMBL
Substance-P receptor	GPCR	P25103	NK1R_HUMAN		Ki	5.06	DRUG MATRIX
Steroid 17-alpha-hydroxylase/17,20 lyase	Enzyme	P05093	CP17A_HUMAN		IC50	7.09	WOMBAT-PK
Potassium voltage-gated channel subfamily A member 3	Ion channel	P22001	KCNA3_HUMAN		IC50	5.22	CHEMBL
Cytochrome P450 2C19	Enzyme	P33261	CP2CJ_HUMAN		IC50	7.80	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	4.50	DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN		IC50	4.18	DRUG MATRIX
Thromboxane-A synthase	Enzyme	P24557	THAS_HUMAN		IC50	7.85	DRUG MATRIX
Bile acid receptor	Nuclear hormone receptor	Q96RI1	NR1H4_HUMAN		IC50	5.49	CHEMBL
Lanosterol 14-alpha demethylase	Enzyme	Q16850	CP51A_HUMAN		IC50	6.89	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.92	CHEMBL
Substance-K receptor	GPCR	P21452	NK2R_HUMAN		Ki	5.47	DRUG MATRIX
Transient receptor potential cation channel subfamily M member 2	Ion channel	O94759	TRPM2_HUMAN		IC50	5.52	CHEMBL
C-C chemokine receptor type 4	GPCR	P51679	CCR4_HUMAN		IC50	5.80	CHEMBL
C-X-C chemokine receptor type 1	GPCR	P25024	CXCR1_HUMAN		IC50	5.70	CHEMBL
Transitional endoplasmic reticulum ATPase	Enzyme	P55072	TERA_HUMAN		IC50	5.85	CHEMBL
Malate dehydrogenase cytoplasmic	Enzyme	P40925	MDHC_HUMAN		IC50	4.46	CHEMBL
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase	Enzyme	Q9UNU6	CP8B1_HUMAN		IC50	6.10	CHEMBL
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.29	DRUG MATRIX
Lanosterol 14-alpha demethylase	Enzyme		CP51_CANAL	INHIBITOR			CHEMBL	CHEMBL
Beta-lactamase	Enzyme		AMPC_ECOLI		IC50	4.70	CHEMBL
Androgen receptor	Transcription factor		ANDR_RAT		Ki	5.11	DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	4.91	DRUG MATRIX
Cysteinyl leukotriene receptor 1	GPCR		CLTR1_CAVPO		Ki	4.78	DRUG MATRIX
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	5.94	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	4.58	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	4.75	CHEMBL
Lanosterol 14-alpha demethylase	Enzyme		CP51_MYCTU		Kd	6.70	CHEMBL
14-alpha sterol demethylase Cyp51A	Enzyme		Q4WNT5_ASPFU		Kd	5.32	CHEMBL
14-alpha sterol demethylase	Enzyme		Q96W81_ASPFM		Kd	6.99	CHEMBL
Indoleamine 2,3-dioxygenase 2	Enzyme		I23O2_MOUSE		IC50	5.23	CHEMBL
Mycocyclosin synthase	Enzyme		CP121_MYCTU		Kd	7.14	CHEMBL
Putative cytochrome P450 130	Enzyme		CP130_MYCTU		Kd	4.88	CHEMBL
Alpha-chymotrypsin	Enzyme		CTRA_BOVIN		IC50	4.07	CHEMBL
Indoleamine 2,3-dioxygenase 1	Enzyme		I23O1_MOUSE		IC50	4.29	CHEMBL
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1	Enzyme		AT2A1_RABIT		Ki	4.46	CHEMBL

External reference:

ID	Source
4018265	VUID
N0000146595	NUI
D00282	KEGG_DRUG
202859	RXNORM
4018265	VANDF
C0009074	UMLSCUI
CHEBI:3764	CHEBI
CL6	PDB_CHEM_ID
CHEMBL104	ChEMBL_ID
DB00257	DRUGBANK_ID
D003022	MESH_DESCRIPTOR_UI
2812	PUBCHEM_CID
2330	IUPHAR_LIGAND_ID
2912	INN_ID
G07GZ97H65	UNII
1284	MMSL
4482	MMSL
d01236	MMSL
002916	NDDF
387325003	SNOMEDCT_US
5797005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0054-4146	LOZENGE	10 mg	ORAL	ANDA	14 sections
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0054-4146	LOZENGE	10 mg	ORAL	ANDA	14 sections
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0054-8146	LOZENGE	10 mg	ORAL	ANDA	14 sections
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0054-8146	LOZENGE	10 mg	ORAL	ANDA	14 sections
Lotrisone	HUMAN PRESCRIPTION DRUG LABEL	2	0085-0924	CREAM	10 mg	TOPICAL	NDA	26 sections
Good Sense Athletes Footantifungal	HUMAN OTC DRUG LABEL	1	0113-0857	CREAM	1 g	TOPICAL	OTC monograph final	13 sections
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0133	CREAM	10 mg	TOPICAL	ANDA	20 sections
Clotrimazole and Betamethasone Dipropionate	HUMAN PRESCRIPTION DRUG LABEL	2	0168-0258	CREAM	10 mg	TOPICAL	ANDA	27 sections
Clotrimazole and Betamethasone Dipropionate	HUMAN PRESCRIPTION DRUG LABEL	2	0168-0370	LOTION	10 mg	TOPICAL	ANDA	20 sections
Fungicure Liquid Gel	HUMAN OTC DRUG LABEL	1	0295-1363	LIQUID	10 mg	TOPICAL	OTC monograph final	9 sections
Fungicure Manicure Pedicure Anti Fungal	HUMAN OTC DRUG LABEL	1	0295-6307	LIQUID	1 mg	TOPICAL	OTC monograph final	10 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0363-0220	CREAM	10 mg	VAGINAL	ANDA	16 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0363-0220	CREAM	10 mg	VAGINAL	ANDA	16 sections
WALGREENS CLOTRIMAZOLE	HUMAN OTC DRUG LABEL	1	0363-1299	CREAM	1 g	TOPICAL	OTC monograph final	11 sections
athletes foot	HUMAN OTC DRUG LABEL	1	0363-1857	CREAM	1 g	TOPICAL	OTC monograph final	13 sections
Walgreens Clotrimazole 3	HUMAN OTC DRUG LABEL	1	0363-2062	CREAM	2 g	VAGINAL	NDA	16 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0363-2105	CREAM	10 mg	TOPICAL	OTC MONOGRAPH FINAL	14 sections
Ringworm	HUMAN OTC DRUG LABEL	1	0363-2107	CREAM	10 mg	TOPICAL	OTC MONOGRAPH FINAL	14 sections
Walgreens Jock Itch	HUMAN OTC DRUG LABEL	1	0363-2109	CREAM	10 mg	TOPICAL	OTC MONOGRAPH FINAL	14 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0363-3492	LIQUID	1 mg	TOPICAL	OTC monograph final	8 sections
Walgreens Clotrimazole Antifungal	HUMAN OTC DRUG LABEL	1	0363-7412	CREAM	1 g	TOPICAL	OTC monograph final	11 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0472-0220	CREAM	10 mg	VAGINAL	ANDA	16 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0472-0220	CREAM	10 mg	VAGINAL	ANDA	16 sections
ClotrimazoleAntifungal	HUMAN OTC DRUG LABEL	1	0472-0350	CREAM	10 mg	TOPICAL	OTC monograph final	13 sections
Clotrimazole and Betamethasone Dipropionate	HUMAN PRESCRIPTION DRUG LABEL	2	0472-0379	CREAM	10 mg	TOPICAL	ANDA	24 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0536-1181	SOLUTION	1 g	TOPICAL	OTC monograph final	13 sections
Rugby Clotrimazole Antifungal Cream	HUMAN OTC DRUG LABEL	1	0536-1265	CREAM	1 g	TOPICAL	OTC monograph final	12 sections
RUGBY ANTIFUNGAL CLOTRIMAZOLE	HUMAN OTC DRUG LABEL	1	0536-1272	CREAM	0.01 g	TOPICAL	OTC monograph final	14 sections
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0574-0107	LOZENGE	10 mg	ORAL	ANDA	18 sections
Major Clotrimazole	HUMAN OTC DRUG LABEL	1	0904-7822	CREAM	10 mg	TOPICAL	OTC monograph final	11 sections